FDA extends approval for GSK’s RSV vaccine, AREXVY, to adults aged 50-59 at increased risk

The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc's (LSE/NYSE: GSK) AREXVY, marking it as the first adjuvanted ... Read More